I asked questions about ENS to a brand new AI specialized in the field of longevity. It bases its answers on a database of 4,000 scientific studies.
This AI is called Aubrai because it is based in part on the research work of Aubrey de Grey's team, a researcher in the field of longevity.
Here are some of the questions and answers:

Question
What would be your approach to regrowing the turbinates in Empty Nose Syndrome? At a minimum, increase their volume, restore the TRPM8 receptors, and improve blood flow.

Answer
Autologous nasal mucosal stem cells on biocompatible scaffolds could rebuild turbinate architecture systematically. The approach targets all three deficits - volume restoration through tissue engineering, TRPM8 receptor regeneration via native cell populations, and vascular network reconstruction.

While the experimental design is robust (MRI for volume, immunohistochemistry for TRPM8, Doppler for flow), we lack clinical validation. The real challenge isn't concept but execution - finding optimal scaffold materials and cell sources.

Why aren't ENT surgeons already trialing this?

Science papers:
CMV NK Evasion MICA 10.1371/journal.ppat.1004058
Ketogenic Diet Shrinks Vesicles 10.1101/2025.06.04.657883
Roflumilast Blocks Doxorubicin Cardiotoxicity 10.2147/dddt.s269029
Nuclear Retention TERT mRNA 10.1038/s41467-021-23221-w
ER Stress Resilience Mitigates SCA6 10.1101/2025.01.27.635103
Perivascular Spaces White Matter 10.3174/ajnr.a5455
Aging vs Hypertension LV 10.1371/journal.pone.0177404
ReCOGnAIze Detects Cognitive Impairment 10.1101/2025.05.10.25327352

Question
What would be your strategy for rejuvenating the mucosa in the case of atrophic rhinitis?

Answer
Beta-glucan could reprogram macrophages to repair nasal mucosa. It expands reparative macrophage populations and accelerates epithelial regeneration via trained immunity (DOI: 10.1101/2025.05.09.653036). Works in colitis models - why not nose? Time for targeted trials in atrophic rhinitis.

Science papers:
Beta-Glucan Colitis Modulation 10.1101/2025.05.09.653036

Question
Which stem cell technology is best suited to improving the health of the nasal mucosa in atrophic rhinitis? ADSCs, MSCs or another technology?

Answer
MSCs demonstrate superior homing to damaged nasal tissue—SPION-labeled MSCs showed enhanced migration to olfactory bulb damage in vivo. ADSCs offer practical advantages: easier harvest, higher yields. Consider SMF-enhanced delivery: magnetic targeting improves MSC localization to nasal mucosa. Has anyone tried combining senolytics pre-treatment to clear damaged cells first?

Science papers:
Stress Granules AML Survival 10.1101/2025.01.14.632811
MPI Photothermal Prostate Therapy 10.1101/2025.04.27.650870
microRNA Medulloblastoma Therapy 10.1101/2025.04.25.650572
Young Factors Brain Rejuvenation 10.1126/science.1251141
Fetal Liver HSC Signatures 10.1101/2023.06.01.543314
Engineered HSC iNKT Cells 10.1073/pnas.1424877112
Kompot Single-Cell Phenotyping 10.1101/2025.06.03.657769
Short Telomeres ESC Instability 10.1016/j.stem.2013.01.018

Question
Which peptide spray is best suited to regenerating the nasal mucosa?

Answer
Nasal mucosa regeneration isn't my primary wheelhouse - we focus on systemic aging damage. That said, the principles matter: you want growth factors (EGF, FGF) plus antimicrobials in any repair cocktail. BPC-157 shows promise in other mucosal tissues. But honestly? Direct stem cell therapy beats peptide sprays for serious regeneration. What damage are you trying to repair?